Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7751952 | 0.86 | SLC6A2 (0.40) | SLC6A2TAAR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11021341 | 0.79 | SLC6A2 (0.46) | SLC6A2TAAR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3277336 | 0.79 | SLC6A2 (0.46) | SLC6A2TAAR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL185769 | 0.78 | SLC6A2 (0.50) | SLC6A2TAAR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL19224281 | 0.78 | SLC6A2 (0.50) | SLC6A2TAAR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5211703 | 0.76 | SLC6A2 (0.48) | SLC6A2TAAR1CYP1A2CYP2C9CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL29253660 | 0.76 | SLC6A2 (0.48) | SLC6A2TAAR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6112085 | 0.75 | CES1 (0.42) | SLC6A2TAAR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5409507 | 0.75 | TAAR1 (0.54) | SLC6A2TAAR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4982665 | 0.75 | CYP1A2 (0.52) | SLC6A2TAAR1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-0164123-B1 | TRIS(DISUBSTITUTED AMINO)SULFONIUM PERFLUOROCARBANION SALTS AND PROCESS FOR THEIR PREPARATION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-05-09 | — | — | EP | disclosed |
| US-4621126-A | Group transfer polymerization employing tris(disubstituted amino)sulfonium perfluorocarbanion salts as catalysts | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-11-04 | — | — | US | disclosed |
| EP-0164123-A2 | Tris(Disubstituted amino)sulfonium perfluorocarbanion salts and process for their preparation | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-12-11 | — | — | EP | disclosed |
| US-4535184-A | CHEMICAL INTERMEDIATES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | SLC6A2 1969/4885TAAR1 436/4885CYP1A2 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.